1. 方法論と範囲
1.1. 調査方法
1.2. 調査目的と調査範囲
2. 定義と概要
3. エグゼクティブ・サマリー
3.1. 治療タイプ別スニペット
3.2. モダリティ別スニペット
3.3. アプリケーション別スニペット
3.4. 患者タイプ別スニペット
3.5. エンドユーザー別スニペット
3.6. 地域別スニペット
4. ダイナミクス
4.1. 影響要因
4.1.1. 推進要因
4.1.1.1. 慢性および急性臓器不全の有病率の上昇
4.1.1.2. 臓器支持デバイスの技術的進歩
4.1.2. 阻害要因
4.1.2.1. 臓器支持療法とデバイスに関連するリスクと合併症
4.1.3. 機会
4.1.4. 影響分析
5. 産業分析
5.1. ポーターのファイブフォース分析
5.2. サプライチェーン分析
5.3. 価格分析
5.4. 特許分析
5.5. 規制分析
5.6. SWOT分析
5.7. アンメット・ニーズ
6. 治療タイプ別
6.1. はじめに
6.1.1. 市場規模分析および前年比成長率分析（%）（治療タイプ別
6.1.2. 市場魅力度指数（治療タイプ別
6.2. 体外式膜酸素療法（ECMO）*市場
6.2.1. 導入
6.2.2. 市場規模分析と前年比成長率分析(%)
6.2.3. 静脈（VV）
6.2.4. 静脈-動脈（VA）
6.2.5. 動脈-静脈（AV）
6.3. 持続的腎代替療法（CRRT）
6.3.1. 持続的動静脈血液濾過療法（CVVH）
6.3.2. 持続的静脈血液透析（CVVHD）
6.3.3. 持続的静脈血液濾過透析（CVVHDF）
6.3.4. 緩徐連続限外濾過（SCUF）
6.4. 体外CO₂除去（ECCO₂R）
6.5. 肝臓支持システム
6.5.1. 分子吸着剤循環システム
6.5.2. バイオ人工肝臓サポート
6.6. 心臓補助装置
6.6.1. 大動脈内バルーンポンプ
6.6.2. 補助人工心臓
6.6.3. 全人工臓器
7. モダリティ別
7.1. はじめに
7.1.1. 市場規模分析および前年比成長率分析（%）, モダリティ別
7.1.2. 市場魅力度指数（モダリティ別
7.2. ポータブル/携帯機器
7.2.1. はじめに
7.2.2. 市場規模分析と前年比成長率分析(%)
7.3. ベッドサイド機器
7.4. 植込み型デバイス
8. 用途別
8.1. 導入
8.1.1. 用途別市場規模分析および前年比成長率分析(%)
8.1.2. 市場魅力度指数、用途別
8.2. 呼吸不全*市場
8.2.1. 序論
8.2.2. 市場規模分析と前年比成長率分析(%)
8.3. 心不全
8.4. 肝不全
8.5. 腎不全
8.6. 多臓器不全
9. 患者タイプ別
9.1. はじめに
9.1.1. 市場規模分析および前年比成長率分析（%）、患者タイプ別
9.1.2. 市場魅力度指数（患者タイプ別
9.2. 成人患者
9.2.1. 序論
9.2.2. 市場規模分析と前年比成長率分析(%)
9.3. 小児患者
9.4. 新生児患者
10. エンドユーザー別
10.1. はじめに
10.1.1. 市場規模分析および前年比成長率分析(%), エンドユーザー別
10.1.2. 市場魅力度指数、エンドユーザー別
10.2. 病院*市場
10.2.1. はじめに
10.2.2. 市場規模分析と前年比成長率分析(%)
10.3. 専門クリニック
10.4. 外来手術センター
10.5. 集中治療室（ICU）
11. 地域別
11.1. はじめに
11.1.1. 地域別市場規模分析および前年比成長率分析(%)
11.1.2. 市場魅力度指数、地域別
11.2. 北米
11.2.1. 序論
11.2.2. 主な地域別ダイナミクス
11.2.3. 市場規模分析および前年比成長率分析（%）（治療タイプ別
11.2.4. 市場規模分析およびYoY成長率分析（%）、モダリティ別
11.2.5. 市場規模分析および前年比成長率分析（%）, アプリケーション別
11.2.6. 市場規模分析およびYoY成長分析(%)、患者タイプ別
11.2.7. 市場規模分析および前年比成長率分析 (%)、エンドユーザー別
11.2.8. 市場規模分析およびYoY成長率分析(%)、国別
11.2.8.1. 米国
11.2.8.2. カナダ
11.2.8.3. メキシコ
11.3. ヨーロッパ
11.3.1. はじめに
11.3.2. 主な地域別動向
11.3.3. 市場規模分析および前年比成長率分析（%）（治療タイプ別
11.3.4. 市場規模分析およびYoY成長率分析（%）、モダリティ別
11.3.5. 市場規模分析および前年比成長率分析（%）, アプリケーション別
11.3.6. 市場規模分析およびYoY成長分析(%)、患者タイプ別
11.3.7. 市場規模分析および前年比成長率分析 (%)、エンドユーザー別
11.3.8. 市場規模分析およびYoY成長率分析(%)、国別
11.3.8.1. ドイツ
11.3.8.2. イギリス
11.3.8.3. フランス
11.3.8.4. スペイン
11.3.8.5. イタリア
11.3.8.6. その他のヨーロッパ
11.4. 南米
11.4.1. はじめに
11.4.2. 地域別主要市場
11.4.3. 市場規模分析および前年比成長率分析（%）（治療タイプ別
11.4.4. 市場規模分析およびYoY成長率分析（%）、モダリティ別
11.4.5. 市場規模分析および前年比成長率分析（%）, アプリケーション別
11.4.6. 市場規模分析およびYoY成長分析(%)、患者タイプ別
11.4.7. 市場規模分析および前年比成長率分析 (%)、エンドユーザー別
11.4.8. 市場規模分析およびYoY成長率分析(%)、国別
11.4.8.1. ブラジル
11.4.8.2. アルゼンチン
11.4.8.3. その他の南米諸国
11.5. アジア太平洋
11.5.1. はじめに
11.5.2. 主な地域別ダイナミクス
11.5.3. 市場規模分析および前年比成長率分析（%）（治療タイプ別
11.5.4. 市場規模分析および前年比成長率分析（%）、モダリティ別
11.5.5. 市場規模分析および前年比成長率分析（%）, アプリケーション別
11.5.6. 市場規模分析および前年比成長率分析 (%)、患者タイプ別
11.5.7. 市場規模分析および前年比成長率分析 (%)、エンドユーザー別
11.5.8. 市場規模分析およびYoY成長率分析(%)、国別
11.5.8.1. 中国
11.5.8.2. インド
11.5.8.3. 日本
11.5.8.4. 韓国
11.5.8.5. その他のアジア太平洋地域
11.6. 中東・アフリカ
11.6.1. 序論
11.6.2. 主な地域別ダイナミクス
11.6.3. 市場規模分析および前年比成長率分析（%）（治療タイプ別
11.6.4. 市場規模分析およびYoY成長率分析（%）、モダリティ別
11.6.5. 市場規模分析および前年比成長率分析 (%)、用途別
11.6.6. 市場規模分析および前年比成長率分析 (%)、患者タイプ別
11.6.7. 市場規模分析および前年比成長率分析 (%)、エンドユーザー別
12. 競合情勢
12.1. 競争シナリオ
12.2. 市場ポジショニング／シェア分析
12.3. M&A分析
13. 企業プロフィール
13.1. Emulate, Inc.*
13.1.1. 会社概要
13.1.2. 製品ポートフォリオと説明
13.1.3. 財務概要
13.1.4. 主な展開
13.2. Baxter International Inc.
13.3. Fresenius Medical Care AG
13.4. Getinge AB
13.5. LivaNova, Inc.
13.6. Asahi Kasei Corporation
13.7. ADVITOS GmbH
13.8. NIHON KOHDEN CORPORATION
13.9. Vapotherm
13.10. Fisher & Paykel Healthcare Limited
リストは網羅的ではありません
14. 付録
14.1. 当社とサービスについて
14.2. お問い合わせ
The global integrated organ support therapies market reached US$ 3.91 billion in 2023 and is expected to reach US$ 5.96 billion by 2031, growing at a CAGR of 5.5% during the forecast period 2024-2031.
Integrated organ support therapies are a multidisciplinary and coordinated set of medical interventions and devices that are designed to sustain, support or temporarily replace the functions of one or multiple failing organs in critically ill patients. These therapies are primarily used in intensive care units and acute care settings where patients suffer from severe health conditions, including multi-organ failure, sepsis, respiratory distress, acute kidney injury or liver failure and among others.
Integrated organ support therapies aim to maintain organ functions to prevent irreversible damage and stabilize patients while underlying causes are treated or the body heals. For instance, according to organdonor.gov, 103,223 men, women and children are on the national transplant waiting list, in such cases, these integrated organ support therapies may be helpful, which further helps to boost the market growth.
Market Dynamics: Drivers
Rising prevalence of chronic and acute organ failures
The increasing prevalence of both chronic and acute organ failures directly correlates with the rising demand for integrated organ support therapies that can manage or replace the function of multiple organs simultaneously, as these conditions significantly increase the need for life-support interventions and multi-organ management. Both chronic and acute organ failures impair the body’s ability to perform essential functions, necessitating integrated organ support devices and therapies that can temporarily replace or support these failing organs.
For instance, according to the study conducted by the National Institute of Health (NIH), the study revealed the incidence of new organ failure at 1,342/1,00,000 person-years and a prevalence of 5.2% of all emergency department contacts. One-year all-cause mortality was 29.8% among organ failure patients. As organ failures are on the rise, the demand for integrated organ support therapies is expected to grow continuously.
Restraints
Factors such as risks and complications associated with organ support therapies and devices, high costs of organ support devices and therapies, complex regulatory approval processes, high maintenance and operational requirements and limited portability and mobility of devices are expected to hamper the integrated organ support therapies market.
While these therapies are essential for managing patients with multi-organ failure, the associated risks, complications and potential side effects can affect their adoption and efficacy. The complexity of using such devices also places an additional burden on healthcare systems, which can hamper the growth of the market.
For instance, one of the most serious complications associated with organ support therapies is the increased risk of infection, especially with invasive devices like extracorporeal membrane oxygenation (ECMO) and continuous renal replacement therapy (CRRT). Many organ support devices, particularly ECMO and CRRT, involve circulating blood outside the body, this further poses a significant risk of blood clot formation or bleeding. These risks may hamper the growth of the market.
Segment Analysis
The global integrated organ support therapies market is segmented based on therapy type, modality, application, patient type, end-user and region.
The multi-organ failure from the application segment accounted for approximately XX% of the global integrated organ support therapies market share
The multi-organ failure segment is expected to hold the largest market share over the forecast period. Integrated organ support therapies are critical in the management of multi-organ failure, a condition where two or more organs fail simultaneously, often resulting from severe infections, trauma or underlying chronic conditions. These therapies provide life-sustaining support to failing organs, enabling doctors to stabilize the patient while the underlying causes are treated or recovery occurs.
For instance, according to a study conducted by ScienceDirect, in surgical critical care units, 50–80% of all deaths are due to multiple organ failure (MOF). The origin of MOF is still not well understood, therapy is still mainly supportive and the death rate (30–70% in most series) has not significantly decreased even though the syndrome was first identified more than 20 years ago. Thus, the rising burden of MOF further increases the demand for integrated organ support therapies.
Geographical Analysis
North America accounted for approximately XX% of the global integrated organ support therapies market share
North America region is expected to hold the largest market share over the forecast period owing to the rising prevalence of chronic diseases and critical illnesses and high healthcare expenditure. Chronic diseases and critical illnesses are the leading causes of organ failure in the region especially in the United States, directly driving the need for integrated organ support therapies. Conditions such as cardiovascular diseases, chronic kidney disease (CKD), diabetes and respiratory diseases significantly increase the incidence of multi-organ failure, where organ support therapies become crucial for patient survival.
For instance, according to the American Kidney Fund Organization, about 808,000 Americans are living with kidney failure. According to the CDC, the US Department of Health and Human Services estimated that 129 million Americans suffer from at least one severe chronic disease.
The U.S. healthcare system is the largest spender on healthcare globally. For instance, according to the U.S. Centers for Medicare & Medicaid Services, US healthcare spending grew 4.1 percent in 2022, reaching $4.5 trillion or $13,493 per person. As a share of the nation's GDP, health spending accounted for 17.3%, which includes significant expenditures on critical care technologies, including ECMO, CRRT and others.
Market Segmentation
By Therapy Type
• Extracorporeal Membrane Oxygenation (ECMO)
o Veno-Venous (VV)
o Veno-Arterial (VA)
o Arterio-Venous (AV)
• Continuous Renal Replacement Therapy (CRRT)
o Continuous Venovenous Hemofiltration (CVVH)
o Continuous Venovenous Hemodialysis (CVVHD)
o Continuous Venovenous Hemodiafiltration (CVVHDF)
o Slow Continuous Ultrafiltration (SCUF)
• Extracorporeal CO₂ Removal (ECCO₂R)
• Liver Support Systems
o Molecular Adsorbent Recirculating System
o Bioartificial Liver Support
• Cardiac Assist Devices
o Intra-aortic Balloon Pump
o Ventricular Assist Devices
o Total Artificial Organs
By Modality
• Portable/Transportable Devices
• Bedside Devices
• Implantable Devices
By Application
• Respiratory Failure
• Cardiac Failure
• Liver Failure
• Kidney Failure
• Multi-Organ Failure
By Patient Type
• Adult Patients
• Pediatric Patients
• Neonatal Patients
By End-User
• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Intensive Care Units (ICUs)
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o The rest of South America
• Asia-Pacific
o China
o India
o Japan
o South Korea
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the integrated organ support therapies market include Emulate, Inc., Baxter International Inc., Fresenius Medical Care AG, Getinge AB, LivaNova, Inc., Asahi Kasei Corporation, ADVITOS GmbH, NIHON KOHDEN CORPORATION, Vapotherm, Fisher & Paykel Healthcare Limited and among others.
Key Developments
In August 2024, Talphera, Inc. declared that the NEPHRO CRRT study's first patient has been recruited. 166 individuals receiving continuous renal replacement therapy (CRRT) at up to 14 clinical locations across the US will be included in the NEPHRO CRRT registrational research. The mean post-filter activated clotting time for circuits injected with nafamostat versus placebo for the first 24 hours is the study's main outcome.
In April 2022, Baxter International Inc. released the U.S. Food and Drug Administration (FDA) 510(k) clearance 0f ST Set for use in continuous renal replacement therapy (CRRT). The ST Set is a disposable, extracorporeal (outside the body) circuit that comes pre-connected and may be used with the PrisMax or Prismaflex control units (monitors). It purifies blood through a semipermeable membrane.
Why Purchase the Report?
• To visualize the global integrated organ support therapies
Market Segmentation based on therapy type, modality, application, patient type, end-user and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of the integrated organ support therapies market with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in excel consisting of key products of all the major players.
The global integrated organ support therapies market report would provide approximately 78 tables, 77 figures and 179 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Therapy Type
3.2. Snippet by Modality
3.3. Snippet by Application
3.4. Snippet by Patient Type
3.5. Snippet by End-User
3.6. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising Prevalence of Chronic and Acute Organ Failure
4.1.1.2. Technological Advancements in Organ Support Devices
4.1.2. Restraints
4.1.2.1. Risks and Complications Associated with Organ Support Therapies and Devices
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Patent Analysis
5.5. Regulatory Analysis
5.6. SWOT Analysis
5.7. Unmet Needs
6. By Therapy Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
6.1.2. Market Attractiveness Index, By Therapy Type
6.2. Extracorporeal Membrane Oxygenation (ECMO)*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.2.3. Veno-Venous (VV)
6.2.4. Veno-Arterial (VA)
6.2.5. Arterio-Venous (AV)
6.3. Continuous Renal Replacement Therapy (CRRT)
6.3.1. Continuous Venovenous Hemofiltration (CVVH)
6.3.2. Continuous Venovenous Hemodialysis (CVVHD)
6.3.3. Continuous Venovenous Hemodiafiltration (CVVHDF)
6.3.4. Slow Continuous Ultrafiltration (SCUF)
6.4. Extracorporeal CO₂ Removal (ECCO₂R)
6.5. Liver Support Systems
6.5.1. Molecular Adsorbent Recirculating System
6.5.2. Bioartificial Liver Support
6.6. Cardiac Assist Devices
6.6.1. Intra-aortic Balloon Pump
6.6.2. Ventricular Assist Devices
6.6.3. Total Artificial Organs
7. By Modality
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
7.1.2. Market Attractiveness Index, By Modality
7.2. Portable/Transportable Devices *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Bedside Devices
7.4. Implantable Devices
8. By Application
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Respiratory Failure*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Cardiac Failure
8.4. Liver Failure
8.5. Kidney Failure
8.6. Multi-Organ Failure
9. By Patient Type
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
9.1.2. Market Attractiveness Index, By Patient Type
9.2. Adult Patients*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Pediatric Patients
9.4. Neonatal Patients
10. By End-User
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.1.2. Market Attractiveness Index, By End-User
10.2. Hospitals*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Specialty Clinics
10.4. Ambulatory Surgical Centers
10.5. Intensive Care Units (ICUs)
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.8.1. U.S.
11.2.8.2. Canada
11.2.8.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.8.1. Germany
11.3.8.2. U.K.
11.3.8.3. France
11.3.8.4. Spain
11.3.8.5. Italy
11.3.8.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.8.1. Brazil
11.4.8.2. Argentina
11.4.8.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.8.1. China
11.5.8.2. India
11.5.8.3. Japan
11.5.8.4. South Korea
11.5.8.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Emulate, Inc.*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Baxter International Inc.
13.3. Fresenius Medical Care AG
13.4. Getinge AB
13.5. LivaNova, Inc.
13.6. Asahi Kasei Corporation
13.7. ADVITOS GmbH
13.8. NIHON KOHDEN CORPORATION
13.9. Vapotherm
13.10. Fisher & Paykel Healthcare Limited
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us
❖ 世界の統合臓器支持療法市場に関するよくある質問(FAQ) ❖
・統合臓器支持療法の世界市場規模は？
→DataM Intelligence社は2023年の統合臓器支持療法の世界市場規模を39.1億米ドルと推定しています。
・統合臓器支持療法の世界市場予測は？
→DataM Intelligence社は2031年の統合臓器支持療法の世界市場規模を59.6億米ドルと予測しています。
・統合臓器支持療法市場の成長率は？
→DataM Intelligence社は統合臓器支持療法の世界市場が2024年～2031年に年平均5.5%成長すると予測しています。
・世界の統合臓器支持療法市場における主要企業は？
→DataM Intelligence社は「Emulate, Inc.、Baxter International Inc.、Fresenius Medical Care AG、Getinge AB、LivaNova, Inc.、旭化成株式会社、ADVITOS GmbH、日本光電工業株式会社、Vapotherm、Fisher & Paykel Healthcare Limitedなど ...」をグローバル統合臓器支持療法市場の主要企業として認識しています。
※上記FAQの市場規模、市場予測、成長率、主要企業に関する情報は本レポートの概要を作成した時点での情報であり、納品レポートの情報と少し異なる場合があります。
